The origin of a clinical evidence platform — built not by a physician, but by someone who works inside the healthcare system and grew tired of watching good science reach clinicians poorly.
Geroevidence was not built by a physician. It was built by someone who works inside the healthcare system — and who grew increasingly frustrated watching the same problem repeat itself in a new domain.
The founder of Geroevidence is a healthcare enterprise and solutions architect — someone who has spent years working at the intersection of clinical operations, payer systems, and health technology. The job involves understanding how clinical and administrative data flows through healthcare organizations, where it gets stuck, where it gets lost, and where decisions get made with incomplete information.
It is a job that gives you a particular view of healthcare — not from the clinical side of the exam room, but from the infrastructure side. You see the systems that support clinical decisions. You see where they work well and where they fail. You develop a sharp sense for the gap between what information exists and what information actually reaches the people who need it.
That gap — good data, poorly synthesized, hard to access — is a recurring theme in healthcare. It shows up in payer-provider data exchanges, in clinical trial recruitment, in quality measurement. And in 2025, it showed up clearly in longevity medicine.
In 2025 the longevity medicine space was simultaneously scientifically serious and informationally chaotic. The PEARL trial had published. The SELECT trial had changed the commercial profile of semaglutide. The TAME trial was enrolling. The hallmarks of aging framework had been updated to twelve hallmarks. The ITP rapamycin lifespan data had been replicated three times across independent NIA-funded sites.
The science was real. The evidence base was growing. And yet the information reaching physicians — the people actually making clinical decisions about rapamycin, metformin, and GLP-1 agonists for their patients — was coming primarily from podcasts, X threads, and supplement company blogs. The gap between the published science and the clinical information environment was striking.
The tools that should have been filling that gap — clinical evidence databases, decision support tools, systematic review services — were either absent from this space entirely or built for disease management rather than longevity medicine. UpToDate covers rapamycin for transplant rejection. It does not cover the PEARL trial. No existing tool was tracking the longevity pharmacopeia as a whole, grading the evidence honestly, and surfacing updates when the evidence changed.
The obvious question is why a healthcare architect and not a physician built this. The honest answer is that the problem Geroevidence solves is not a clinical problem — it is an information architecture problem. The science exists. The trials are published. The evidence is accessible. The problem is synthesis, organization, and delivery.
That is a problem that someone who builds information systems for a living is well positioned to solve — perhaps better positioned than a physician who is busy seeing patients. The clinical judgment required to practice longevity medicine belongs to physicians. The infrastructure required to keep those physicians current on the evidence is a different skill set.
Geroevidence does not attempt to substitute for clinical judgment. It attempts to ensure that the evidence informing that judgment is accurate, current, and honestly graded. The physician brings the expertise. Geroevidence brings the synthesis.
Every significant design decision in Geroevidence followed from a single constraint: the product should be trustworthy to a physician who knows the science better than we do.
That constraint ruled out a lot. No clinical recommendations — because a physician who knows more about rapamycin than we do does not need us to tell them what to prescribe. No unsourced claims — because a physician who reads the primary literature will immediately spot an unsupported assertion. No inflated evidence tiers — because overstating Emerging evidence as Moderate or Strong would be caught immediately by anyone who has read the trials.
It also defined the aesthetic. The medical journal format — serif headlines, monospaced numerals, hairline rules, dated profiles — is not decoration. It is a signal to the physician reader that this tool takes the evidence as seriously as they do. The Bloomberg Terminal reference is deliberate: a tool built for sophisticated professional users who need accurate real-time data, not a consumer wellness app built for general audiences.
Geroevidence launched in 2026 with six interventions, seven evidence profiles, and a literature feed that updates within twenty-four hours of new publications. The scope will expand as the field expands — new interventions as the evidence base develops, deeper trial coverage as more longevity-specific trials report, and expanded editorial coverage of the science underpinning each compound.
The most watched trials in longevity medicine right now — PEARL-2, TAME, TRITON — will report over the next two to four years. When they do, Geroevidence will update every affected profile immediately. That is the promise: a living reference that moves when the evidence moves.
The goal is not to be the most comprehensive longevity database. It is to be the most trustworthy one — the reference a physician reaches for when they need to know what the evidence actually says, not what someone wants it to say.
Questions, corrections, or feedback: hello@geroevidence.com. We read everything.